Laboratorio Reig Jofre SA (RJFE)

Madrid
4.560
-0.040(-0.87%)
  • Volume:
    35,323
  • Bid/Ask:
    4.530/4.700
  • Day's Range:
    4.530 - 4.690
  • Type:Equity
  • Market:Spain
  • ISIN:ES0165359029

RJFE Overview

Prev. Close
4.6
Day's Range
4.53-4.69
Revenue
230.37M
Open
4.68
52 wk Range
3.6-6.347
EPS
0.07
Volume
35,323
Market Cap
350.82M
Dividend (Yield)
0.05
(0.98%)
Average Vol. (3m)
32,357
P/E Ratio
66.28
Beta
0.43
1-Year Change
12.15%
Shares Outstanding
76,935,267
Next Earnings Date
Oct 29, 2021
What is your sentiment on Laboratorio Reig Jofre SA?
or
Market is currently closed. Voting is open during market hours.

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesSellSellStrong SellStrong SellSell
Technical IndicatorsStrong SellStrong SellStrong SellStrong SellBuy
SummaryStrong SellStrong SellStrong SellStrong SellNeutral

Laboratorio Reig Jofre SA Company Profile

Laboratorio Reig Jofre SA Company Profile

Employees
1122
Market
Spain

Laboratorio Reig Jofre SA, formerly Natraceutical SA, is a Spain-based company primarily engaged in the research, development, manufacturing and marketing of drugs. The Company’s activities are divided into four business divisions: Industrial Services, providing production services for third parties; Pharma, selling own pharmaceuticals under a range of brands, such as Reig Jofre, Medea, Orravan, Bioglan and Sala; Reaserch and Development (R&D) and Regulatory, including the development of indications for existing molecules, as well as generics and molecular diagnostics, among others; and Biotech, offering biopharmaceutical support services, such as analytical and process development, quality control and assurance, as well as stability studies. The Company also provides nutritional cosmetics, and food supplements, among others. It operates worldwide in Europe, Africa, the Americas, Australia and Asia through a number of subsidiaries, including Chiesi Espana SA and Oryzon Genomics SA.

Read More
  • https://reigjofre.com/en/
    1
    • https://es.investing.com/equities/natraceutical-sa-commentary
      1
      • any opinion here please ?
        1
        • https://es.investing.com/equities/natraceutical-sa-commentary
          1
      • Nov 2019: Profits 45% less than same six-months period in 2018. EBITDA 17% more.
        2
        Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
        Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.